Keyphrases
Drug Sensitivity
100%
Ovarian Carcinoma Cells
100%
Flavonoids
100%
Ovarian Cancer Cells
100%
ERK2
100%
Platinum Drugs
100%
Tumor Microenvironment
80%
Ovarian Cancer
60%
Extracellular Signal-regulated Kinase
40%
Platinum Sensitivity
40%
Ovarian Cancer Screening
40%
Platinum Compounds
40%
Platinum-resistant Ovarian Cancer
40%
Cellular Components
20%
Blockage
20%
Drug Resistance
20%
Cancer Cells
20%
Quercetin
20%
Standard of Care
20%
Most Common Form
20%
Reduced Sensitivity
20%
Patient's Will
20%
Survival Rate
20%
Paclitaxel
20%
Chemoresistance
20%
Poor Survival
20%
Colchicine
20%
Kinase Activity
20%
Acquired Resistance
20%
Advanced Stage
20%
Platinum-based Chemotherapy
20%
Gynecologic Malignancies
20%
Human Mesenchymal Stem Cells (hMSCs)
20%
Carboplatin
20%
Platinum Resistance
20%
Phosphorylated Extracellular Signal-regulated Kinase
20%
Resistance to Therapy
20%
MEK1 Inhibitor
20%
Adipocyte Progenitor Cells
20%
Toxicity Resistance
20%
Fisetin
20%
Platinum Drug Resistance
20%
Platinum(IV) Prodrugs
20%
Medicine and Dentistry
Flavonoid
100%
Drug Sensitivity
100%
Carcinoma Cell
100%
Ovarian Cancer
100%
Krukenberg Tumor
100%
Cancer Cell
62%
Tumor Microenvironment
50%
Drug Resistance
37%
Mitogen-Activated Protein Kinase
37%
Chemotherapy
25%
Mitogen Activated Protein Kinase 3
25%
Platinum Derivative
25%
Mesenchymal Stem Cell
12%
Adipocyte
12%
Quercetin
12%
Paclitaxel
12%
Cancer
12%
Survival Rate
12%
Colchicine
12%
Cancer Therapy
12%
Cancer Diagnosis
12%
Carboplatin
12%
Progenitor Cell
12%
Ovarian Cancer Cell Line
12%
Prodrug
12%
Platinum-Resistant Ovarian Cancer
12%
Platinum-Sensitive Ovarian Cancer
12%
Fisetin
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
100%
Ovary Cancer
100%
Flavonoid
100%
Tumor Microenvironment
44%
Drug Resistance
33%
Mitogen Activated Protein Kinase
33%
Mitogen Activated Protein Kinase 3
22%
Platinum Derivative
22%
Malignant Neoplasm
11%
Paclitaxel
11%
Survival Rate
11%
Chemotherapy
11%
Colchicine
11%
Prodrug
11%
Quercetin
11%
Carboplatin
11%
Fisetin
11%